Why Xeris Biopharma Shares Are Rising Today
Why Xeris Biopharma Shares Are Rising Today
Xeris Biopharma Holdings Inc (NASDAQ:$Xeris Pharmaceuticals(XERS.US)$) is trading higher Friday morning after the company announced U.S. Food and Drug Administration approval of Recorlev for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Xeris Biophma控股公司(納斯達克：$Xeris製藥公司(XERS.US)$)股價週五早盤走高，此前該公司宣佈美國食品和藥物管理局(FDA)批准雷科列夫(Recorlev)用於治療庫欣綜合徵成年患者的內源性高皮質醇血癥。
The approval of Recorlev was based upon safety and efficacy data from two positive Phase 3 studies.
Recorlev的批准是基於兩項積極的3期研究的安全性和有效性數據。
The study titled "SONICS" met its primary and key secondary endpoints, significantly reducing and normalizing mean urinary free cortisol concentrations without a dose increase.
這項名為“超音速”的研究達到了主要和關鍵的次要終點，在不增加劑量的情況下顯著降低和正常化了平均尿遊離皮質醇濃度。
The study titled "LOGICS" also met its primary and key secondary endpoints, confirming the efficacy and safety of Recorlev in normalizing and maintaining therapeutic response compared with the placebo.
這項名為“Logics”的研究也達到了主要和關鍵的次要終點，證實了與安慰劑相比，Recorlev在正常化和維持治療反應方面的有效性和安全性。
"With this approval, Xeris' experienced endocrinology-focused commercial organization can begin rapidly working to help address the needs of Cushing's syndrome patients in the U.S. who are treated with prescription therapy," said Paul Edick, chairman and CEO of Xeris Biopharma.
他説：“有了這一批准，Xeris公司經驗豐富、專注於內分泌學的商業組織可以開始迅速開展工作，幫助解決美國庫欣綜合徵患者的需求，這些患者正在接受處方藥治療。”保羅·埃迪克，Xeris Biophma董事長兼首席執行官。
HC Wainwright & Co. analyst Oren Livnat maintained Xeris Biopharma with a Buy rating and raised the price target from $4.25 to $5.40.
SVB Leerink analyst Roanna Ruiz maintained Xeris Biopharma with an Outperform rating and raised the price target from $6 to $8.
HC Wainwright&Co.分析師Oren Livnat維持Xeris Biophma的買入評級，並將目標價從4.25美元上調至5.40美元。
SVB Leerink分析師羅安娜·魯伊斯(Roanna Ruiz)維持Xeris Biophma的評級為跑贏大盤，並將目標價從6美元上調至8美元。
Xeris Biopharma is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology.
Xeris Biophma是一家生物製藥公司，為內分泌學、神經學和胃腸病學領域的患者羣體開發和商業化獨特的療法。
See Also: 5 Stocks To Watch For December 31, 2021
另見：2021年12月31日值得關注的5只股票
XERS Price Action: Xeris has traded as low as $1.77 and as high as $7.94 over a 52-week period.
XERS價格操作：Xeris的交易價格低至1.77美元，52周內高達7.94美元。
The stock was up 24.30% at $3.02 at time of publication.
截至發稿時，該股上漲24.30%，至3.02美元。